Summary.-Irrespective of the ethnic origin of the patient, nasopharyngeal carcinoma (NPC), appears to stimulate the production of IgA antibodies against VCA. These antibodies are detected at high frequency and titres in sera from NPC patients but only rarely from control subjects. A majority of relapse-free survivors tested 1-12 years after radiotherapy (RT) sustain a detectable level of IgA anti-VCA. Serum titres of IgA anti-VCA remain relatively unchanged in individual NPC patients after RT, regardless of the disease evolution. These antibodies were detected in serum from one individual 9 months before NPC and the titre rose concomitantly with its clinical onset.
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Titres of IgA anti -VCA in multiple serum specimens from individual NPC patients, and in sera from different NPC patients, do not correlate with titres of IgG anti -VCA or with Serum IgA. It thus seems possible that the IgA anti-VCA in the sera of NPC patients might be largely derived near NPC.
Apparently healthy individuals showing detectable IgA anti-VCA tend to aggregate in families of NPC patients. The distribution of siblings of these families who have the IgA anti-VCA reaction shows the binomial distribution expected for an autosomal recessive trait, implying the involvement of an autosomal recessive gene in the IgA anti -VCA response.
THE IgA antibody response to EpsteinBarr virus-determined antigens seems to be an outstanding feature of nasopharyngeal carcinoma (NPC). Serum IgA concentration was found to be significantly higher in NPC patients than in control subjects (Wara et al., 1975; Ho et al., 1976) . Henle and Henle (1976) reported that NPC patients have high titres of IgA antibody against viral capsid antigen (VCA) (Henle and Henle, 1966) and early antigens (EA) (Henle et al., 1970) . These reactivities are detected less frequently and occur at lower titres in sera from patients with Burkitt's lymphoma (BL) and infectious mononucleosis (IM). Both BL and IM, like NPC, are closely associated with EBV, such that all 3 groups of patients have comparably high titres of IgG antibodies against VCA (Henle and Henle, 1976) . Moreover, EBV is a ubiquitous virus, such that all the healthy Chinese subjects which served as one of the control groups in our previous studies had serum IgG antibodies against VCA, but none had detectable IgA antibodies . IgA antibody against VCA was detected in the saliva from a majority of NPC patients, but not from healthy subjects or patients with other cancers (Ho et al., 1977) . Desgrange and de The (1977) also reported similar findings and, as suggested by these authors, such antibodies might have interfered with the isolation of EBV from the throat washings of NPC patients. By contrast, it was shown by Gerber et al. (1972) that EBV is readily isolated from the throat washings of IM patients.
It is apparent from the above that this feature may have diagnostic applications, and understanding of the mechanisms underlying such response may yield information on the state of infection with EBV in NPC. In this paper, we report results of our horizontal and longitudinal studies with NPC patients before and after radiotherapy (RT), and with family members of these patients, who have a higher risk of this disease than family members of patients with other cancers (Ho, 1972 Sera or plasma were obtained from Chinese NPC patients before and after RT, and from their apparently healthy family members. The Tunisian and Caucasian NPC patients' sera were kindly provided by Dr G. de The, International Agency for Research on Cancer (IARC), Lyon, France. Control sera were obtained from healthy subjects (HS) consisting of blood donors and traumatic-ward patients due for discharge. Also included as controls were sera from patients with other cancers (OC). All specimens from Hong Kong subjects were stored at -70°C and thawed once immediately before use. Those from IARC were packed in dry ice, despatched by air and stored at -70°C upon arrival.
IgG and IgA antibodies against VCA were determined by indirect immunofluorescent technique using FITC-conjugated, heavy,-chain-specific goat anti-human sera (Dako, Denmark). Titres are expressed as the reciprocal of the maximum serum dilution which gives a positive immunofluorescence. IgA concentration was determined by radial immunodiffusion as previously described (Ho, et 6l., 1977 The association between NPC and IgA antibody against VCA was further investigated in NPC patients before RT, in their apparently healthy family members, and in HS and OC patients. Sera or plasma from these subjects were tested for this reactivity at a dilution of :10 (Table I) . A high frequency of detection of IgA anti-VCA is clearly associated with NPC. There is a higher frequency of detection (X2 6X13, P < 0 02, DF 1) (Figs. 4 and 5) . It was shown in Table I (Thompson and Thompson, 1966) . This (Klein et al., 1974) which may be activated by treatment with halogenated nucleotides to synthesize EBV antigens and viral particles (Glaser et al., 1976; Trumper, Epstein and Giovanella, 1976) . Local production of IgA anti-VCA may account for the high frequency of detection of these antibodies in saliva and throat washings from NPC patients (Ho et al., 1977; Desgranges and de The, 1977) . Some of these locally produced antibodies might also be expected to reach the systemic circulation. If this were to occur extensively relative to the systemically produced antibodies, a general lack of correlation between serum IgA anti-VCA titre and IgA protein concentration might be anticipated, because the level of the largely locally-derived antibodies in the serum is not expected to be related to the overall activity of the systemic IgA immune system as reflected in the serum IgA concentrations. Serum IgG anti-VCA on the other hand, may be largely produced systemically and may thus reflect the intensity of systemic stimulation by VCA. The apparent lack of correlation between titres of serum IgA and IgG anti-VCA is thus compatible with different sites of production of these antibodies. The local production of IgA and IgG antibodies has been further studied by us. The results to be reported in the future show that there is a frequent occurrence of IgA plasma cells in NPC biopsy specimens, while IgG plasma cells were detected less frequently.
In an earlier study of concentrated saliva from NPC patients, we reported that the IgA antibodies in the majority of these specimens lacked the secretory piece, and it was speculated that this might reflect their systemic origin (Ho et al., 1977) . This is contrary to the results of similar studies by Desgrange and de who found that, in most instances, secretory pieces were associated with the IgA antibodies in the throat washings from NPC patients. This discrepancy between the results of these studies could be possibly due to dissociation of the secretory pieces from the IgA molecules during concentration, or to a difference in the antisera against the secretory piece used in these studies (de The, personal communication). We are currently attempting to resolve this discrepancy.
The observed frequency of detection of IgA anti-VCA in the sibs of NPC falls between those of NPC patients and controls. It may be inferred from the one instance described earlier of a sib of an NPC patient who had detectable IgA anti-VCA before clinical onset of NPC, and from the persistence of this reactivity in the relapse-free NPC survivors after RT, that the apparently healthy sibs with detectable IgA anti-VCA may harbour subclinical NPC. On the other hand, NPC patients' siblings with detectable IgA anti-VCA showed the binomial distribution pattern expected for the distribution of an autosomal recessive trait in sibships of different sizes. This is consistent with a possible genetic involvement in the IgA antibody response to VCA (Thompson and Thompson, 1966) . Whichever the reason for the high frequency of detection may be, it is important to carry out a detailed study of EBV serology among the sibs of NPC patients and this is being pursued.
